Perceptronix - Early Diagnosis, Better Outcomes
   
   

News

September 24, 2012 - Perceptronix Announces Publication of Important Clinical Study Evaluating its Oral Cancer Detection Test

Perceptronix Medical Inc. (PMI) today announced that positive results from the study evaluating OralAdvance™ quantitative cytology test for early detection of oral cancer are published in the September 2012 issue of Oral Surgery, Oral Pedicine, Oral Pathology and Oral Radiology.

The study reports clinical experience with the test in community setting, evaluating its performance in reference to clinicohistopathologic features. It finds the chair-side procedure "non-agressive, quick, and minimally painfull". Sensitivity and specificity of OralAdvance™ in the detection of high-risk potentially malignant disorders and squamous cell carcenoma were found to be 87% and 97% respectively.

OralAdvance™ is a quanitative cytology test, based on measurement of DNA content and abnormal duclear morphology from samples, taken by dentists from suspicious lesions using special brush. "Our data demonstrate high sensitivity and specificity of quantitative cytology in identification of high-risk epithelial lesions that require immediate care in a community setting", stated Dr Samsong Ng, lead author of the paper and oral pathology consultant at PMI.

"We are very pleased with the results of this study, which establishes OralAdvance™ as an effective new tool suitable for use in dental or medical practice", commented Dr. Bojana Turic, President and CEO of PMI. "Unfortunately, to date the majority of oral cancers are detected in late stages." "The need for this test in the dental community is huge", adds Dr. Alexi Doukine, Director of Business Development and Clinical Affairs at PMI. "We believe that this method will make a difference in improving early detection of oral cancer worldwide as we are actively working on forming international partnerships on use of this technology. The publication of the study results is also very timely. We just have launched the test in Canada as part of Second Step Laboratory Services in partnership with LED Dental, maker of fluroescent visualization device VELscope, bringing these two innovative oral cancer detection technologies together". "The speed and ease of this chair-side procedure enables Second Step Laboratory Services to significantly improve on the already high standard of oral health care that VELscope clinics offer their patients." said Peter Whitehead, CEO of LED Dental Inc..

The paper appears in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, Volume 114, Issue 3 (September 2012 issue), which is the official publication for the American College of Oral and Maxillofacial Surgery, American Academy of Oral and Maxillofacial Radiology, American Academy of Oral Medicine, and the American Academy of Oral and Maxillofacial Pathology.


About Perceptronix Medical Inc.

Perceptronix Medical Inc. ("PMI") provides anatomic pathology and cancer diagnostics services to medical and dental practices and facilities in support of earlier diagnoses for better patient outcomes.

The company uniquely specializes in early cancer detection using quantitative cytology, computer-aided measurement of large-scale DNA abnormality that can indicate precancerous or cancerous changes. PMI has developed two proprietary tests using its ClearCyte™ technology.

For further information contact:
Alexei Doudkine
Director, Business Development & Clinical Affairs
PMI Labs
Suite 400 - 555 West 8th Avenue
Vancouver, BC, V5Z 1C6
Phone: 604-629-8785 x.231
Email: alexei.doudkine@pmilabs.com

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

News and Events